Fulcrum Therapeutics (NASDAQ:FULC) Price Target Raised to $25.00

Fulcrum Therapeutics (NASDAQ:FULC) had its price target boosted by HC Wainwright from $18.00 to $25.00 in a research report sent to investors on Monday morning, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Fulcrum Therapeutics’ FY2028 earnings at $0.94 EPS and FY2029 earnings at $1.91 EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and set a $23.00 target price (up from $16.00) on shares of Fulcrum Therapeutics in a research report on Monday. Leerink Partners set a $20.00 price target on Fulcrum Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Truist Financial set a $14.00 price objective on shares of Fulcrum Therapeutics in a research note on Monday, November 24th. Finally, Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 1st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Fulcrum Therapeutics has an average rating of “Hold” and a consensus price target of $18.50.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $13.80 on Monday. The stock has a market cap of $746.86 million, a price-to-earnings ratio of -11.69 and a beta of 3.17. The company has a 50 day moving average of $9.65 and a 200-day moving average of $8.03. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Equities research analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the completion of the transaction, the director owned 484,864 shares in the company, valued at $5,348,049.92. This represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the sale, the insider directly owned 6,053,960 shares of the company’s stock, valued at $84,634,360.80. This represents a 40.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Algert Global LLC lifted its holdings in shares of Fulcrum Therapeutics by 6.0% in the first quarter. Algert Global LLC now owns 36,147 shares of the company’s stock valued at $104,000 after purchasing an additional 2,030 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after acquiring an additional 2,677 shares in the last quarter. Strs Ohio boosted its position in Fulcrum Therapeutics by 3.7% during the 3rd quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after acquiring an additional 2,800 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Fulcrum Therapeutics by 2.6% during the 1st quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock worth $356,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after purchasing an additional 3,697 shares during the last quarter. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.